STOCK TITAN

Astera Labs (ALAB) files Form 144 for 33,000-share sale via Morgan Stanley

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Astera Labs, Inc. (ALAB) filing a Form 144 notifies a proposed sale of 33,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $6,012,600.00. The shares were acquired 11/30/2018 in a private acquisition from the issuer and paid in cash. The filing lists multiple prior 10b5-1 sales by related trusts and entities between 06/20/2025 and 07/21/2025, including individual sales of 51,000, 58,000, 29,000 and others. The signer represents no undisclosed material adverse information and cites a Rule 10b5-1 trading plan context where applicable.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Notice of a planned 33,000-share sale by an insider-account holder; prior 10b5-1 executions show active disposals in June–July 2025.

The filing is a routine disclosure under Rule 144 showing a proposed sale of 33,000 shares valued at $6.01M, executed through Morgan Stanley Smith Barney LLC on NASDAQ. The securities were originally acquired in 2018 from the issuer in a private transaction and paid in cash, which supports their non-restricted provenance. Multiple 10b5-1 sales listed for related trusts and entities between 06/20/2025 and 07/21/2025 indicate ongoing liquidation activity by affiliated holders. For investors, this is informational rather than a company operational disclosure; materiality is limited to potential share supply into the market.

TL;DR: Proper Rule 144 notice filed; acquisition history and 10b5-1 disclosures are documented, with no disclosure of undisclosed material information.

The form provides the required representations under Rule 144, including the signer’s attestation they possess no undisclosed material adverse information. The record shows the securities were a private acquisition from the issuer on 11/30/2018, paid in cash, which typically satisfies the holding period and provenance tests for resale. The schedule of recent 10b5-1 sales for multiple related accounts is clearly reported, demonstrating compliance with prearranged trading plans. From a governance and disclosure perspective, the filing appears procedurally complete for the transaction described, with no statements beyond the required representations.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What shares is ALAB planning to sell under this Form 144?

The notice states a proposed sale of 33,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with aggregate market value of $6,012,600.00.

When were the shares being sold originally acquired?

The shares were acquired on 11/30/2018 in a private acquisition from the issuer and payment was made in cash.

Are there recent related sales reported in the filing for ALAB?

Yes. The filing lists multiple 10b5-1 sales by related trusts and entities between 06/20/2025 and 07/21/2025, with individual sales such as 51,000, 58,000, and 29,000 shares.

Who is the broker handling the proposed sale?

The broker of record is Morgan Stanley Smith Barney LLC, located at Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filer state they possess any undisclosed material information?

The filer signs a representation that they do not know any material adverse information about the issuer that has not been publicly disclosed.
ASTERA LABS INC

NASDAQ:ALAB

View ALAB Stock Overview

ALAB Rankings

ALAB Latest News

ALAB Latest SEC Filings

ALAB Stock Data

20.41B
150.74M
Semiconductors
Semiconductors & Related Devices
Link
United States
SAN JOSE